Facebook Twitter YouTube Google Plus

A.) Effective Advocacy and the Case for Federal Meso Research Funding

Kathleen Wiedemer, Interim Executive Director, Meso Foundation

Kathy Wiedemer comes to the Meso Foundation with over twenty years of non-profit management experience.  It is important to her to work in an organization where she has a passion for the mission and so has concentrated her efforts in academic and healthcare institutions and also in an organization where she believes she can make an impact.  In addition to being president of the University Community Hospital Foundation in Tampa, Florida, she also headed the Bethesda Hospital Foundation in Boynton Beach, Florida.  She was Executive Director of Development for the Lombardi Comprehensive Cancer Center at Georgetown University and also headed the development operation at the ASCO Cancer Foundation.  Under her leadership, organizations have raised more than $75 million to advance their missions.  She has broad experience working with not-for-profit boards and in staff development. 

Kathy feels it is a privilege to be associated with the Meso Foundation, help the organization relocate, become established and thrive in our nation’s capital.

Kathy holds a Masters in Education from Nazareth College in Rochester, NY and a Masters in Business Administration from the University of South Florida in Tampa, FL.  She has also earned the designation of Certified Fund Raising Executive.


Click here to view the slides for "Effective Advocacy and the Case for Federal Meso Research Funding" by Kathy Wiedemer, MBA.

 

This video will be posted soon!

© 2009 Mesothelioma Applied Research Foundation, Inc. All rights reserved. 501(c)(3)

A.) Effective Advocacy and the Case for Federal Meso Research Funding

B.) State Assistance on Insurance Appeals

C.) Cancer Genetics in the Mesothelioma Family

D.) Fundraising

E.) Navigating Mesothelioma Clinical Trials with GPS (Getting Personalized Service)

F.) Update from Across the Pond

G.) The Mesothelioma Experience: Patient and Provider Perspectives Panel

H.) Work of the Science Advisory Board

J.) Present and Future of Mesothelioma Treatment: Medical Oncologist and Researcher Perspective

K.) New Developments in Radiation Oncology: A Global Perspective

M.) Pain Management

Mesothelioma Treatment: Present & Future from a Surgeon & Research Perspective | Dr. Harvey Pass

N.) Traditional Healing with Modern Science

O.) Update on Clinical Trials and Mesothelioma Research

P.) Mesothelioma Tissue Bank

Photodynamic Therapy for Mesothelioma Treatment | Dr. Joseph Friedberg

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

R.) The Use of Cytokine Inhibitors: Translational Lab Results

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion